|

Immune Checkpoint Inhibitors Clinical Trials

6 actively recruiting trials

▲ +1 trial since June 2026

Pipeline

Phase 2: 2Phase 4: 1Phase 1/2: 1

Top Sponsors

  • University Hospital, Basel, Switzerland1
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
  • Shunda Du1
  • Peking Union Medical College Hospital1
  • Hospital Universitario Araba1

Indications

  • Cancer6
  • Immune-Related Adverse Events2
  • Liver Disease1
  • Inflammatory Myopathies1
  • Lupus Erythematosus, Systemic1

Other6 trials

A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
Phase 2
Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge
Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients
Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
Phase 2
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
Phase 1/2
Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.